Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood cancer
Pharma
BeOne’s Brukinsa hits goal in lymphoma confirmatory trial
Overall survival data will likely be key in BeOne’s approval bid, given Imbruvica’s earlier U.S. withdrawal in MCL.
Angus Liu
Jun 30, 2026 6:00am
BeOne boosts support for Blood Cancer United with $5M commitment
Jun 26, 2026 3:57am
Lilly oncology chief ‘blown away’ by new Jaypirca CLL data
Jun 15, 2026 8:25am
AbbVie scores FDA green light for another ImmunoGen asset
May 28, 2026 7:27am
BeOne's Venclexta challenger Beqalzi nets FDA approval
May 13, 2026 4:45pm
Lilly touts Jaypirca fixed-duration win in ‘ambitious’ CLL trial
Apr 13, 2026 10:16am
